ImmunoGen, Inc. Announces Webcast of its Investment Community Meeting on February 25, 2010
WALTHAM, Mass., Feb 03, 2010 (BUSINESS WIRE) -- ImmunoGen, Inc. (Nasdaq: IMGN), a biopharmaceuticals company that develops targeted anticancer therapeutics using its Targeted Antibody Payload (TAP) technology, invites investors, journalists and the general public to listen to a live webcast of the Company's investment community meeting on February 25, 2010. The webcast will begin at 8:30 am ET and may be accessed through the Investor Information section of the Company's website, www.immunogen.com. The meeting is expected to last approximately three hours, including a short break. An archive of the webcast will be available on the Company's website through March 11, 2010.
About ImmunoGen, Inc.
ImmunoGen, Inc. develops targeted anticancer therapeutics using its expertise in tumor biology, monoclonal antibodies and the creation and attachment of potent cancer-cell killing agents. The Company's TAP technology uses antibodies to deliver one of ImmunoGen's cancer-cell killing agents specifically to tumor targets. In addition to the Company's product pipeline, compounds utilizing the TAP technology are in clinical testing through ImmunoGen's collaborations with Genentech (a wholly owned member of the Roche Group), sanofi-aventis, Biogen Idec and Biotest. The most advanced compound, trastuzumab-DM1 (T-DM1), is in Phase III testing being conducted by Genentech and Roche. Other ImmunoGen collaborative partners include Bayer HealthCare and Amgen. More information about ImmunoGen can be found at www.immunogen.com.
SOURCE: ImmunoGen, Inc.
ImmunoGen, Inc.
For Investors:
Carol Hausner, 781-895-0600
Executive Director, Investor Relations
and Corporate Communications
info@immunogen.com
or
For Media:
Yates Public Relations
Kathryn Morris, 914-204-6412
